National HealthCare (NHC): Reassessing Valuation After Outperform Rating Reaffirmed Despite Recent Insider Share Sale

Simply Wall St.2025-12-20

National HealthCare (NHC) is back on investors radar after fresh commentary reiterated its Outperform rating, crediting the move to strong financial results and a constructive technical setup, despite...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592113968?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice2-main-header/1585186569462","is_english":true,"pubTime":"2025-12-20 05:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592113968","market":"us","top_or_hot":-1,"title":"National HealthCare (NHC): Reassessing Valuation After Outperform Rating Reaffirmed Despite Recent Insider Share Sale","media":"Simply Wall St.","content":"<div>\n<p>National HealthCare (NHC) is back on investors radar after fresh commentary reiterated its Outperform rating, crediting the move to strong financial results and a constructive technical setup, despite...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nysemkt-nhc/national-healthcare/news/national-healthcare-nhc-reassessing-valuation-after-outperfo\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>National HealthCare (NHC): Reassessing Valuation After Outperform Rating Reaffirmed Despite Recent Insider Share Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNational HealthCare (NHC): Reassessing Valuation After Outperform Rating Reaffirmed Despite Recent Insider Share Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-20 05:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nysemkt-nhc/national-healthcare/news/national-healthcare-nhc-reassessing-valuation-after-outperfo><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>National HealthCare (NHC) is back on investors radar after fresh commentary reiterated its Outperform rating, crediting the move to strong financial results and a constructive technical setup, despite...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nysemkt-nhc/national-healthcare/news/national-healthcare-nhc-reassessing-valuation-after-outperfo\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NHC","symbol_name":"National Healthcare Corp","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nysemkt-nhc/national-healthcare/news/national-healthcare-nhc-reassessing-valuation-after-outperfo","article_id":"2592113968","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice2-main-header/1585186569462"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nysemkt-nhc/national-healthcare/news/national-healthcare-nhc-reassessing-valuation-after-outperfo","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2592113968","pubTimestamp":1766179105,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"National HealthCare (NHC) is back on investors radar after fresh commentary reiterated its Outperform rating, crediting the move to strong financial results and a constructive technical setup, despite a recent insider share sale.\nSee our latest analysis for National HealthCare.\nThat upbeat view lines up neatly with the market action, with the share price now at $141.67 and a 30 day share price return of 12.30 percent feeding into a robust year to date gain of 33.05 percent. The three year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"NHC":"National Healthcare Corp","NHC.AU":"NEW HOPE CORP LTD"},"translate_title":"国家医疗保健（NHC）：尽管最近出售了内部股票，但在重申跑赢大盘评级后重新评估估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NHC":1.5,"NHC.AU":1.5},"content_text":"National HealthCare (NHC) is back on investors radar after fresh commentary reiterated its Outperform rating, crediting the move to strong financial results and a constructive technical setup, despite a recent insider share sale. See our latest analysis for National HealthCare. That upbeat view lines up neatly with the market action, with the share price now at $141.67 and a 30 day share price return of 12.30 percent feeding into a robust year to date gain of 33.05 percent. The three year total shareholder return of 149.51 percent underlines that momentum has been building for some time rather than just on this latest insider headline. If this kind of steady healthcare compounder appeals to you, it could be worth scanning healthcare stocks to spot other operators showing similar resilience and improving sentiment in today’s market. Yet with National HealthCare trading near record highs and boasting hefty multi year returns, is the market still underestimating this steady compounding story, or has the share price already baked in its next leg of growth? Most Popular Narrative Narrative: 21.2% Undervalued DanielGC sees National HealthCare’s fair value well above the recent 141.67 dollars close, framing today’s price as a potential entry point before sentiment catches up. This narrative explores the perspective that the market is mispricing NHC due to a short-term issue, which some investors may view as creating an attractive entry point. It assumes the company will recover its net income and the market will re-rate its valuation. Read the complete narrative. Curious how steady double digit growth, recovering margins and a richer earnings multiple combine into that upside target. Want to see the exact roadmap behind it. Result: Fair Value of $179.8 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, persistent labor cost inflation or tougher Medicare and Medicaid reimbursement could squeeze margins longer than expected and stall the anticipated valuation re rating. Find out about the key risks to this National HealthCare narrative.  Build Your Own National HealthCare Narrative If you are not fully aligned with this view, or want to dig into the numbers yourself, you can build a tailored story in minutes: Do it your way. A great starting point for your National HealthCare research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision. Ready for more compelling investment ideas? Before you move on, lock in your next opportunities with the Simply Wall St Screener so you are not the one saying you missed it.  Capitalize on mispriced opportunities by targeting these 914 undervalued stocks based on cash flows where strong cash flows are not yet fully appreciated by the market. Capture innovation at the edge of technology with these 25 AI penny stocks that could reshape how industries operate and scale. Strengthen your income stream by focusing on these 13 dividend stocks with yields > 3% that combine reliable payouts with solid underlying businesses.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTechValuation is complex, but we're here to simplify it.Discover if National HealthCare might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592113968","isCrawlerRequest":true}